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Abstract
This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and
Lasmiditan target the trigeminovascular system and respectively, are characterized in the
gepant and ditan classes of pharmaceuticals. Based on a review of studies, Rimegepant was
determined to be the advantageous acute treatment. This is not conclusive due to inequivalent
comparison in sample size and amount of research completed. It is encouraged for additional
research to be imposed before a conclusive determination of the advantageous acute
treatment can be distinguished.
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MIGRAINE PRIMARY HEADACHE OVERVIEW
Introduction to Primary Headaches
The research of primary headache disorders elicits several limitations due to being frequently
diagnosed with inadequate pathogenesis comprehension. The primary headaches can be
distinguished into four categories including tension type headaches, migraines, trigeminal
autonomic cephalalgias, and other primary headache disorders1 2. In epidemiological studies,
the number of diseased cases within a population is measured by the prevalence. The global
prevalence for primary headaches is approximately 50%3 4, however several regions of the
world are not included in this average due to the lack of available data5. Reiterating the
limitations exhibited in primary headache research, geographical gaps hinder an accurate
quantification of individuals afflicted globally4 6. Nonetheless, when comparing published
reputable studies, tension type headaches and migraines were found to be the most globally
recurring. Tension type headache episodes are described to be bilateral obtaining a mild to
moderate intensity. They are characterized into chronic and episodic; chronic lasting greater
than 15 days and episodic lasting from a few hours up to a few days7. Episodic can further be
subdivided into infrequent and frequent categories, with the latter requiring 10 episodes
minimal between the time-span of 1-14 days/ month2. Contrastingly, migraines are
distinguished into aura and without aura classifications – both recurrent lasting 4-72 hours. As
defined in the International Classification of Headache Disorders (ICHD), migraines without
aura are indicative of a unilateral location, pulsating quality, moderate or severe intensity,
nausea and/or photophobia and phonophobia2. Migraines with aura are similarly unilateral,
but obtain visual, sensory, or other central nervous system symptoms that are reversible2 8.
Discriminating between migraines and tension type headaches is often difficult within a
clinical setting due to simultaneous occurrence of attacks in patients who get headaches
1

frequently. Due to this, a recent development of more specific criteria was established by the
ICHD for differentiation of the phenotypic resemblance of migraines and tension type
headaches exhibited in some patients2. This additional criterion allows for diagnosis precision
in the health care setting, thus improving clinical research as well.
A retrospective systemic study was conducted by the Global Burden of Disease in 2016
estimating the prevalence of tension type headaches at 30.8% and migraines at 18.9%5.
According to this study, although the tension type headaches are more prevalent, migraines
have a larger implication of disease burden. A disease burden can be quantified because it is
directly proportional to disability weights. Disability weights are defined as the disabling
consequence and it is measured by the percentage of health lost during an attack, in
comparison to a person with full health. Globally, the disease weight for migraines are
significantly greater. They estimate to be around 43.4%, while the disease weight for tension
type headaches are around 3.7%5. With migraines obtaining such a high degree of burden
followed by a high prevalence, there is a significant need in migraine research development
for pharmacological advancements. Conflict is induced because migraine primary headaches
are independent of underlying medical conditions and lack causative pathology9. By
determining causative pathology, more drugs can be developed directly targeting the source of
affliction, thus resulting in reduced burden amongst populations. Various implications
regarding migraine pathology have been the focal point of many studies for this goal, but
despite advances in research the genesis remains unknown. There has been lethargic
progression of innovative migraine medications to aid in the control of disease burden and
temporarily eradicate pain. New medications have emerged targeting the potential inflicted
origin of migraines for acute medicinal purposes. The purpose of this research aims to
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evaluate two contemporary medications that may be primitive in decreased affliction
worldwide. A brief overview of hypotheses that represent the premise of migraine
pharmacology will be included in order to better elucidate the mechanistic actions of the new
medications. Rimegepant and Lasmiditan target the trigeminovascular system, characterizing
within the gepant and ditan classes of pharmaceuticals, respectively. Their mechanisms of
attack within the trigeminovascular system will be contrasted. The advantageous acute
treatment will be determined based on a review of study evaluations and side effects
associated.
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AN OVERVIEW OF PROPOSED MIGRAINE HYPOTHESIS
Although pathogenesis of migraines are unknown, neurological changes exhibited during migraine
attacks have assisted tremendously in the development of potential drug targets. Historically, a
proposed hypothesis by Thomas Willis indicated that migraine etiology solely involved the
vasodilation of arterioles, which led to development of the vascular theory10. Based on
experimentation the vascular theory is credible in some regard, but it can be refuted. Drugs inducing
vasoconstriction are quite effective in treatment. Contrastingly, drugs inducing cranial vasodilation,
such as nitroglycerine, have been shown to cause hypersensitivity to noxious somatosensory
stimulation11. Although vasodilation and hypoperfusion of blood flow does occur within migraines,
evidence shows this is not the primitive reason for affliction. In fact, vasoactive intestinal peptide
(VIP) is a transmitter that imposes cranial vasodilation, but there is evidence of migraines not
triggered as a result of intravenous VIP infusion12 13. Regardless, it can be stated that vasodilation is a
part of a migraine triggering cascade that causes an increase in the release of neuropeptides promoting
neurogenic inflammation and noxious stimulation.
Trigeminovascular system in migraines
The neuropeptide release and resulting inflammation that typically appears during a migraine attack is
a focal point in generation of drug targets. The mechanistic action leading to the release of
neuropeptides remain debatable and unknown. Many hypotheses focus on different mechanistic
pathways involved with Dural vasculature and the trigeminovascular system. The discovery by Ray
and Wolff in 1940 showed that electrical and mechanical stimulation of the dura mater generated
pain14. The dura mater of the meninges is where the bulk of meningeal afferents are located,
innervated with nociceptors. This coincides with the early work completed by Ray and Wolff,
because nociceptors encode for noxious stimuli. It is stated that a triggering event sensitizes and
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activates trigeminal nociception, while releasing several neuropeptides that promote neurogenic
inflammation and vasodilation. Triggering stimuli such as stress, fatigue, not eating on time,
environmental stimuli, and hormonal changes may be indicative of generating this response15 16 13 17.
The cell bodies of the meningeal afferents are within the trigeminal ganglion. The transmitted
information from the meningeal afferent axons are delivered primarily through the ophthalmic branch
of the trigeminal nerve, but a small amount of information is transmitted through the mandibular and
maxillary branches as well16. From here, it is stated that the trigeminal nerve conveys sensory
information from intracranial structures, and there is apparent evidence that extracranial structure
sensory information is conveyed as well18. Using electrophysiological techniques with rats as the
model organism, several studies indicated that pericranial tissues are effected in noxious stimulation19
20

. In continuance with the pathway, information is then delivered into the spinal trigeminal nucleus

for relay. The spinal trigeminal nucleus can be subdivided into three distinct parts, with each relaying
a different sensory modality. The subnucleus paralis and subnucleus interparalis both relay
discriminative tactile information of the trigeminal nerve, while the subnucleus caudalis is
responsible for pain and temperature21. Figure 1 provides a depiction of this process. This theory is a
plausible explanation for migraine occurrence but does not account for additional stimulation that
occurs in other neuronal anatomical features. Not only this, but evidence shows various other
physiological changes that occur during migraines are pertinent to the type (aura and without aura).
This further introduces supplemental proposed hypotheses.
Hypothalamus and Brainstem Activation in Migraine
Hypothalamic and brainstem nuclei activation is a significant physiological occurrence during
spontaneous migraine attack. Substantial evidence shows the involvement of persistent activation and
increased blood flow to the hypothalamus and brainstem using positron emission tomography22 23 24.
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A study conducted with animal models indicated that there is direct control on spontaneity of the
spinal trigeminal nucleus via the paraventricular hypothalamic nucleus25. Similarly, brainstem nuclei
activation is correlated with migraine because it is proposed to result in either the enhancement or
inhibition of neurons facilitating trigeminovascular pain transmission in the spinal and medullary
dorsal horn26 27 28. The mechanism of action for the modulation of the brainstem to migraines is
unspecific, despite occurrence being prevalent during attack. Within Figure 1, the link between
hypothalamic and brainstem activation to the trigeminovascular system is evident.
Mast Cell Degranulation in Migraine
A diverged hypothesis from Dural and trigeminovasculature innervation involves the mast cells
which are proliferated around the meningeal afferents in the dura mater. A trigger response may
degranulate the mast cells to release pro-inflammatory mediators leading to the release of sensory
peptides from meningeal nociceptors13 16. There are two considerations when discussing mast cell
degeneration. Some state that mast cell degeneration results from neuropeptide release from
meningeal afferents13 26. However, there are implications that mast cells can initiate nociceptor
sensitizing neuropeptide release16. Migraines can be triggered by hormonal input, and mast cell
degranulation occurs in response to the binding these hormonal peptides to the expressed
progesterone and estrogen receptors on their surface16. Figure 2 provides a depiction of both
pathways. This research is not conclusive, but the degranulation of mast cells in migraine allow it to
be a potential target in migraine pharmacology.
Aura Physiological Changes in Migraine
As stated earlier, migraine without aura are characterized by photophobia and phonophobia. Evidence
has showed a slight increase in blood flow within the brainstem regions and the visual and cingulate
auditory cortices29. Interestingly, there seems to be an affiliation with the brainstem increased
6

perfusion of blood in aura migraine attacks as well30. A discrepancy that is distinctive to migraine
aura attacks is a physiological process entitled cortical spreading depression (CSD). Cortical
spreading depression is depicted by a disruption of electrical activity across the cortical grey matter
surface of the brain, resulting in suppressed neural activity29 31. This disruption is characterized by
high extracellular potassium concentration and influx of sodium and chloride. It is linked to migraine
with aura because it slowly propagates within the primary visual cortex, generating a retinotopic
visual percept32. Evidence also shows that CSD can be a triggering factor for activation and
sensitization of the trigeminovascular system, thus inducing neurogenic inflammation13. Research
remains pertinent regarding the mechanism for CSD. It has been implied that sensitization of the
blood brain barrier results from CSD30, and increases the brain’s sensitivity to neuropeptides in order
to trigger migraines. This has been refuted by experimentation, but the speculation of CSD causing
sensitization remains.
Neuropeptide Secretion in Migraine
An association of all the variant proposed migraine triggering cascades is the increased release of
vasoactive neuropeptides at nerve endings. The release is dependent on the type of nerve fiber that
innervates the dura vasculature. Parasympathetic and sympathetic nerve fibers are innervated
throughout the dura resulting in the potential release of various neuropeptides. The parasympathetic
fibers typically release vasoactive intestinal peptide, Neuropeptide Y, Acetylcholine, and nitric oxide
synthase. The sympathetic fibers of the dura stimulate the release of norepinephrine, neuropeptide Y,
as well as ATP33. Trigeminal sensory nerves typically release the neuropeptides calcitonin generelated peptide (CGRP), Neurokinin A, Pituitary adenylate cyclase-activating peptide (PACAP),
nitric oxide synthase, and substance P which coexists in the nerve terminal with serotonin (5-HT)34.
Serotonin is not only located within these nerve terminals, but it is interspersed throughout the
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trigeminovascular system35. The serotonin neurotransmitter is assumed to play a role in migraine due
to an altered concentration during an attack. The mechanism of action and high or low concentration
amount remains debatable. Historically, high levels of 5-hydroxyindoleacetic (a serotonin precursor)
was found in the urine36 which was presumed to equate to lower abundance of serotonin in the brain.
Low serotonin levels have also been linked to intensifying sensory processing information such as the
primary auditory cortex36. Contrastingly, other research proves that the plasma levels of the serotonin
precursor does not affect the abundance of serotonin in the brain. Recently, a study was published that
tracked serotonin levels indirectly using positron emission tomography. A serotonin receptor (5-HT4)
was radiolabeled and could be quantified as inversely proportional to the serotonin levels. The results
hypothesized that high levels of serotonin are possibly a result or trait of migraine37. The various
hypotheses imposed on serotonin levels in migraine elicits the importance of continued migraine
research. Serotonergic receptors are successful drug targets for mitigating pain. Stronger targets
directly impacting serotonin concentration can be developed when the physiological effects and
mechanisms are concluded. See Table 1 for the neurotransmitters released correspondent to the nerve
fiber as listed above.
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A NEW APPROACH TO ACUTE MIGRAINE PHARMACOLOGY
Impact of Development
Acute migraine treatment is sufficient for short term relief with patients who experience
recurrent migraines lasting within the range of 4-72 hours for short term relief. This treatment
is typically effective in migraines with aura and without aura. A commonly used over the
counter medication are nonsteroidal anti-inflammatory drugs (NSAIDS). As stated earlier,
neurogenic inflammation is a characteristic occurrence during a migraine attack. Upon
inflammation, prostaglandin secretion is implied to elicit sensitization of nociceptors in the
brain38. Cyclooxygenase is the enzyme responsible for the conversion of arachidonic acid into
prostaglandins, which stimulate pain generation and inflammation. Based on experimentation,
both cyclooxygenase 1 and 2 can be found in the dura of the meninges38. The inhibition of
Cyclooxygenase via NSAIDs can prevent the cascade of nociceptor activation and pain.
NSAIDs are only utilized if the patient attains a mild to moderate intensity migraine39,
therefore other acute migraine treatments should be used for those in which NSAIDs are
rendered ineffective. Commonly used stronger migraine medications include ergot derivatives
and triptans. These are non-specific 5-HT1D/1B agonists obtaining a slight amount of selectivity
to the 5-HT1F receptor. These agonists play a role in vasoconstriction of arterioles35. Due to
this vasoconstriction property of triptans and ergot derivatives, inflicted individuals with
cardiovascular problems are eliminated from use. The development of specific drugs would
thus make mitigation of migraine accessible to all. Rimegepant and Lasmiditan, were recently
developed to manage the degree of affliction worldwide. See Table 2 for a depicted
differentiation between the drug classes developed.
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Rimegepant
As stated in the preceding sections, neuropeptide release is a key component in migraine
occurrence due to promotion of neurogenic inflammation and noxious stimulation. CGRP is a
proinflammatory vasodilator that is released from trigeminal nerve fibers to bind to CGRP
receptors. There is an additional CGRP binding receptor entitled AMY1 that is imposed to
have an similar binding strength as the CGRP receptor, given they are in the same family40 41
42

. AMY1 is classified as an adrenomedullary receptor, and all receptors in this class are

capable of binding CGRP. The gepant classification of pharmaceuticals is characterized by
antagonistic properties towards the CGRP receptor, which should eliminate the activation of
the migraine triggering cascade. Gepants are preferable alternatives to acute migraine
treatment due to the lack of vasoconstrictive properties that the triptans and ergot derivatives
attain. Conflict arose when the clinical development of gepants was temporarily halted due to
liver toxicity upon exposure43. Evidence coincides with the liver toxicity resulting from
development of a potential metabolite byproduct of the drug, so a new drug creation was
necessary that rid this property. The ensuing development was Rimegepant – recently
approved by the FDA in February 202044.
Mechanism of Action
The exact mechanism for Rimegepant binding is unknown, but like other gepants, it is an
antagonist to the CGRP receptor (see Figure 3). A recent study was conducted and stated
Rimegepant obtained an affinity to the CGRP receptor 65 times higher than the
adrenomedullin receptors40. They indicated that if AMY1 and additional adrenomedullin
receptors played a role in the CGRP activation cascade with equivalence, Rimegepant would
not be effective. However, this can be refuted. A recent in vitro study within Cos7 transfected
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cells was conducted, which tested the ability of Rimegepant to antagonize against AMY1 and
additional adrenomedullin receptors45. This study elucidated that binding occurred to both
receptors. Because the study did not take place in human subjects or animal models, a vast
amount of limitations is prevalent when analyzing. Additional experimentation should be
completed for a better understanding of Rimegepant targeting and mechanism of action.
Evaluation of Studies
Several studies were completed measuring the safety and efficacy of Rimegepant (75 mg oral
tablet administered) in migraine treatment by utilizing various methods. One 12-week study
estimated the safety of Rimegepant as a preventative treatment by simultaneously
administering monoclonal antibodies. There were 16 patients that were screened for the study,
but only 13 began treatment, and only a total completion of 10. It was stated that two of the
participants who dropped the study gave no indication of why, but the remaining participant
elicited lack of efficacy for the drug. Of the 13 individuals that began treatment, the average
age of all patients was approximately 49.9 years with 11/13 women participants46. The
participants had to be afflicted with at least 2-8 migraines per month in order to be involved
with the study. Three different types of monoclonal antibodies were used, and the patients
were given the medication for approximately 4 weeks. It was concluded that this combination
was safe and more effective than singular monoclonal antibody use. One of the major
limitations of this study was the small sample size. A small sample size is not generalizable,
therefore additional experimentation should be done before normalizing concomitant use of
Rimegepant and monoclonal antibodies as a migraine prevention method.
A larger study included 1186 individuals with the intent being to measure the efficacy of
Rimegepant solely. The study was not measured overtime, but rather in a single occurrence,
18

and was also double-blind. This implies that some individuals received the Rimegepant, while
others received a placebo. The administers nor participants could distinguish the difference
between the two samples. In order to participate in the study, all participants had to have a
history of migraine that occurred about 2-8 times per month for at least a year. The number of
individuals no longer experiencing pain after oral ingestion of Rimegepant was measured after
a time frame of two hours (indicated relief period). The demographics of the participants were
predominantly female and an average age of 40.6 years old. Upon attack, patients recorded
answers to questions in an electronic diary which pertained to the undergoing symptoms,
bothersome features during attack like nausea, phonophobia, and photophobia, as well as
ratings pertinent to the intensity of pain47. The results indicated that approximately 19.6% of
the patients who received the Rimegepant experienced relief of pain and 12.0% that received
the placebo experienced relief of pain. Also, results showed that approximately of patients
who took Rimegepant had a 37.6% of diminished bothersome symptoms after 2 hours. This
was significantly higher than the placebo that was administered which had a 25.2%
bothersome symptom relief. There were many limitations within this study, but a major
limitation was frequency of recorded data. Earlier, I established how the study was not based
overtime, but on one occurrence. There is a lack of credibility because measurement overtime
allows for consistency or inconsistency of the results to be determined.
Adverse Effects
The adverse effects caused by Rimegepant use differed for both studies enlisted above. When
patients simultaneously used monoclonal antibodies and Rimegepant, 2 out of 13 individuals
experienced nasopharyngitis which was rendered a normal adverse effect. Others experienced
back pain, dizziness, sinusitis, myalgia, contusion, and a first-degree AV block46. These
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effects were individualized – only inflicting one patient. The AV block could have possibly
been associated with the treatment, which is a plausible downside given that Rimegepant was
created to be a more universally used drug in comparison to the triptans. Due to the small
sample size, generalized conclusions cannot be made, further advocating for more research.
When analyzing the study that screened 1811 participants, cardiovascular adverse effects were
not prevalent. However, it is important to note that subjects who obtained cardiovascular
disease were eliminated from the study, therefore conclusion upon adverse cardiac effects on
inflicted patients cannot be determined. The significant effects with a 1% incidence greater
than placebo included nausea and urinary tract infections.
Lasmiditan
Mechanism of Action
Lasmiditan was developed October of 201948 in efforts to target migraines more selectively in
comparison to triptans and ergot derivatives. Categorized in the ditan class of
pharmaceuticals, Lasmiditan aims to act as an agonist towards the 5-HT1F receptor to prevent
the occurrence of neurogenic inflammation within the migraine triggering cascade49 (see
Figure 4). Lasmiditan was determined to be a quite effective treatment that could be
universally applicable to patients due to the lack of vasoconstriction properties that triptans
and ergot derivatives obtain. When discussing the effects of the 5-HTF receptor within the
trigeminovascular system, there is indication that it acts centrally and peripherally35. This is
primarily due to the location of the receptors being in both the trigeminal ganglion, as well as
the nucleus caudalis. Additional details of Lasmiditan discuss its implicated effects throughout
the cascade. Due to the agonistic effects of 5-HTF, CGRP release can possibly be inhibited
along with other neurotransmitters.
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Evaluation of Studies
To determine the efficacy of treatment with and without concomitant prevention methods, a
double-blind study was conducted including 3981 participants. Three different doses of
Lasmiditan (50 mg, 100 mg, or 200 mg) and a placebo was administered to participants
randomly. The criteria applicable was each participant had to be afflicted with 3-8 migraines
per month and had to be over the age of 18. The mean age of participants was 45.7 years, and
primarily women were involved in the study. In order to analyze efficacy, patients received an
electronic journal in which they answered questions pertaining to the pain they experienced
throughout attack, burden imposed due to attack, and effectiveness after the medication. The
results elicited that patients experienced significant effectiveness when taking Lasmiditan
compared to the placebo51. 698 of 3981 patients were established to use prevention
medications if they were taking beta blockers, epileptic medications, and anti-depressants for
a total of three months. The results did not establish a statistical significance between
concomitant use and sole use, proving the compound is effective without the addition of a
preventative treatment. A major limitation of this study was that although two trials were
completed, only one utilized the 50 mg Lasmiditan dosage. This adds a lack of consistency
within the study.
Another study completed determined the safety and efficacy of Lasmiditan amongst
individuals who obtain cardiovascular risk factors52. Approximately 77.9% of the participants
had at least one cardiovascular risk. The criteria were similar to the study described above. It
consisted of individuals who were afflicted with 3-8 migraines per month and at least 18 years
of age. Lasmiditan dosage at 100 mg and 200 mg, along with a placebo was randomly given
to 1856 participants and data was analyzed via an electronic diary 2 hours post medication
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ingestion. The results indicated that 32.2% of patients were free of migraine pain after
Lasmiditan and 15.3% were free after placebo. The most bothersome symptom was also
quantified with participants having 40.7% relief after ingesting the Lasmiditan and 29.5% of
individuals experiencing relief after ingesting the placebo. A limitation within this study was
that there was only a comparison of Lasmiditan with 100 mg and 200 mg in patients with
cardiovascular risk. The effect of cardiovascular risk on a 50 mg Lasmiditan tablet was not
deduced, which could have further proved effectiveness.
Adverse Effects
The adverse effects included in each Lasmiditan study were not unexpected. The first study
had effects of dizziness, paresthesia, somnolence, fatigue, nausea, muscle weakness and
hypoesthesia. The rates for individuals taking preventative medications were very similar. The
other study had effects of dizziness, paresthesia, somnolence, fatigue, hypoesthesia, nausea,
and lethargy. The incidence was higher than 2% in every Lasmiditan group for these effects,
and greater than the placebo group52. This study also included the incidence of cardiovascular
anomalies. These cardiovascular effects were quite low in comparison, comprising of
palpitations, sinus bradycardia, tachycardia, and left ventricular hypertrophy.
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DISCUSSION
It is evident that increased research is crucial to determine migraine pathogenesis for
production direct targeting medications. However, the acute treatments discussed do not
provide pain relief to all patients. As stated earlier, prophylactic treatments include the usage
of monoclonal antibodies when discussing CGRP antagonists. Monoclonal antibodies have
shown to be effective towards patients with medically intractable migraines53. Additionally, a
recent advancement has showed that neuromodulation has been very effective towards
patients who are resistant to the migraine acute treatments discussed. Neuromodulation is a
technique in which there is imposed electrical stimulation on various anatomical structures.
The stimulated areas that have proven to be effective for intractable migraines include the
occipital nerve, vagus nerve, sphenopalatine ganglion, supraorbital nerve, transcutaneous
vagus, and transcranial magnetic stimulation54. These techniques provided are conducive to
the subset of patients who experience contraindications and resistance to acute treatments.
All the Rimegepant and Lasmiditan studies evaluated in this research were quite similar and
were promising in terms of effectiveness and safety. However, a lot of unknowns are
prevalent. The full mechanistic action of Rimegepant is unknown, and studies linking
effectiveness towards cardiovascular patients have not yet been demonstrated. Similarly, the
complete mechanistic action of Lasmiditan is unknown, and various adverse effects are
presumable based on the evaluated studies. When reviewing the concomitant use of
Rimegepant with preventative treatment (monoclonal antibodies), it was proposed
Rimegepant increased efficacy. When reviewing the concomitant use of Lasmiditan with
preventative treatments (beta blockers, epileptic medications, and anti-depressants), the
efficacy was not increased and remained the same. Additionally, in the second Lasmiditan
26

study evaluated, the adverse effects included dizziness, paresthesia, somnolence, fatigue,
hypoesthesia, nausea, and lethargy. Not only this, but these adverse effects obtained an
incidence of greater than 2% when comparing to the placebo. In comparison, the doubleblind study of Rimegepant indicated only nausea and urinary tract infections as the adverse
effects with an incidence higher than 1% compared to the placebo. Based on these results, it
can be stated that Rimegepant is the advantageous acute treatment. This is not conclusive due
to several limitations regarding fair comparisons. When comparing drugs, prices can have a
huge effect on whether they are deemed more advantageous or not. Comparing two drugs
elicits individualized perspectives. The sample sizes are not equivalent, which can account
for a misnomer in adverse effects. There has yet to be a study showing the cardiovascular
effects of Rimegepant upon at risk participants which can cause additional adverse effects
that are not yet established. Also, very little clinical trials on Rimegepant are developed due
to its recent approval. Therefore, it is encouraged for additional research to be imposed
before a conclusive determination of the advantageous acute treatment can be distinguished.
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CONCLUDING REMARKS
Based on the results established in this study, Rimegepant appears to be the advantageous acute treatment.
This is not conclusive due to inequivalent comparison in sample size and amount of research completed. It
is encouraged for additional research to be imposed before a conclusive determination of the advantageous
acute treatment can be distinguished.
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